Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | -0.00% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | +0.00% |
About
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Target Price
The average target price of AURA is 16.2 and suggests 158% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre